The primary objective of the study was to assess the feasibility of randomising men to a trial of HIFU versus RP with a recruitment target of 80 men. In total, 87 men consented to join the PART study, and 82 of these men went onto be randomised. Patients will be followed up for a total of 3 years as per protocol, with the final follow-up expected to take place in May 2020. The PART research team now plan to submit an application to undertake the main, larger RCT comparing clinical, cost-effectiveness, and quality of life outcomes between radical treatments and PA.
The PART study, a feasibility study comparing radical prostatectomy (RP) and partial ablation (PA) using HIFU of the prostate in men with unilateral, intermediate risk prostate cancer has now completed recruitment.
